Tag: DehydraTECH drug delivery technology

Lexaria Announces Voluntary Delisting from the Canadian Securities Exchange to Concentrate Trading on the Nasdaq Capital

MotherlodeTV
Lexaria Bioscience

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE: LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces that on June 30, 2021 it made a request to voluntarily delist its common shares from the Canadian Securities Exchange (the “CSE”). It is expected that the close of business on Wednesday, July 7, 2021 will be the final trading day for Lexaria on the CSE. At the open of the trading day on July 8, 2021, the Company’s shares will only trade on the NASDAQ Capital Markets (‘Nasdaq’). read more

Lexaria Hits Important Anti-Viral Milestone with In Vitro Test of DehydraTECH(TM)

MotherlodeTV
Lexaria Bioscience

Lexaria Bioscience Corp. (CSE;LXX) hit a major milestone this week with their patented DehydraTECHTM technology. An IC50 in vitro study was completed with COVID-19 SARS-CoV-2 antivirals Remdesivir and Ebastine and concluded that their formulation and processing methodology “did not negate the known efficacy of those compounds.” read more

Lexaria Drug Delivery Platform Enables up to Three-Fold Increase in Oral Delivery of Antiviral Drugs

DehydraTECH™ improves delivery into bloodstream of orally administered remdesivir and ebastine in study VIRAL-A20-2
MotherlodeTV
Lexaria Bioscience

Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (CSE:LXX) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce positive results from its tolerability and pharmacokinetic (“PK”) animal study VIRAL-A20-2, evaluating DehydraTECH-enabled remdesivir and ebastine. read more

Lexaria Provides Progress Report on Six R&D Programs

-All studies are using DehydraTECH™ 2.0 formulations for multiple market applications, including antivirals, hypertension, NSAIDs and oral nicotine -These studies are part of Lexaria’s 2021 applied R&D program intended to enable opportunities for strategic partnerships
MotherlodeTV
Lexaria Bioscience

Lexaria Bioscience Corp. (Nasdaq: LEXX) (Nasdaq: LEXXW) (CSE: LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, provides this progress report on several studies within its 2021 applied research and development (R&D) program. Other studies actively underway and planned will be reported on separately. read more

Lexaria Issues Progress Report on First Human Clinical Study of 2021, HYPER-H21-1

Dosing is complete in first of three human clinical studies hoped to validate Lexaria’s patented technology for hypertension relief – Study tested an advanced “DehydraTECH™ 2.0” CBD formulation – Second human clinical study, HYPER-H21-2, to commence immediately
MotherlodeTV
Lexaria Bioscience

Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (CSE:LXX) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to report that treatment and dosing in its human clinical study (HYPER-H21-1) have been completed ahead of schedule. read more

Lexaria’s DehydraTECH(TM)-Enabled Remdesivir and Ebastine Effectively Inhibit the COVID-19 SARS-CoV-2 Virus

MotherlodeTV
Lexaria Bioscience

Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces that remdesivir and ebastine processed with DehydraTECH were effective at inhibiting the COVID-19 SARS-CoV-2 virus using an in vitro screening assay in infected cells in Lexaria study VIRAL-C21-3. read more

Lexaria DehydraTECH(TM) 2.0 Outperforms MCT in 2021 R&D Study

MotherlodeTV
Lexaria Bioscience
info

New York, New York–(Newsfile Corp. – May 25, 2021) – PCG Digital –The positive results keep rolling in for Lexaria (LXX). They recently released R&D study results for three new DehydraTECHTM 2.0 formulation variations that significantly outperformed traditional MCT oil-based formulations that have become CBD industry standard. read more

Lexaria’s Newest DehydraTECH(TM) 2.0 Formulation Tested in Study HYPER-A21-2 Demonstrates Its Strongest CBD Absorption Results Ever

New formulation delivers up to 2,708% more CBD into bloodstream* – Human clinical hypertension study HYPER-H21-1 also progressing
MotherlodeTV
Lexaria Bioscience

Lexaria Bioscience Corp. (Nasdaq: LEXX) (Nasdaq: LEXXW) (CSE: LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce successful test results of two new “DehydraTECH™ 2.0” cannabidiol (“CBD”) formulations in its second 2021 applied research and development study program, HYPER-A21-2. read more